Undislosed ADC therapeutic / ImmunoPrecise - LARVOL DELTA

ImmunoPrecise Antibodies and a Global Biotechnology Leader Enter into a USD $8M-$10M Partnership for the Development of Novel Cancer Therapeutics. (Businesswire) - "ImmunoPrecise Antibodies Ltd...is pleased to announce a strategic partnership with a leading biotechnology company with a multi-billion-dollar market capitalization to advance the discovery and development of Antibody-Drug Conjugates (ADCs) and bispecific antibodies for the treatment of cancer. This collaboration focuses on leveraging contract research expertise while integrating IPA’s proprietary B-cell Select platform and artificial intelligence-driven discovery capabilities to enhance the efficiency and precision of therapeutic development...Under the terms of the agreement, the partnership will encompass the discovery, lead characterization, optimization, and preclinical-grade production of multiple antibody-based therapeutics..."

Preclinical • Oncology